- Home
- MLR vs TBPH Comparison
MLR vs TBPH Comparison
Compare MLR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- TBPH
- Stock Information
- Founded
- MLR 1990
- TBPH 2013
- Country
- MLR United States
- TBPH United States
- Employees
- MLR N/A
- TBPH 97
- Industry
- MLR Construction/Ag Equipment/Trucks
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- MLR Consumer Discretionary
- TBPH Health Care
- Exchange
- MLR Nasdaq
- TBPH Nasdaq
- Market Cap
- MLR 492.7M
- TBPH 652.2M
- IPO Year
- MLR 1994
- TBPH N/A
- Fundamental
- Price
- MLR $43.09
- TBPH $13.15
- Analyst Decision
- MLR Strong Buy
- TBPH Strong Buy
- Analyst Count
- MLR 1
- TBPH 3
- Target Price
- MLR $64.00
- TBPH $21.33
- AVG Volume (30 Days)
- MLR 133.7K
- TBPH 307.4K
- Earning Date
- MLR 08-06-2025
- TBPH 08-12-2025
- Dividend Yield
- MLR 1.85%
- TBPH N/A
- EPS Growth
- MLR N/A
- TBPH N/A
- EPS
- MLR 3.64
- TBPH 0.26
- Revenue
- MLR $975,860,000.00
- TBPH $77,205,000.00
- Revenue This Year
- MLR N/A
- TBPH $51.74
- Revenue Next Year
- MLR $19.06
- TBPH N/A
- P/E Ratio
- MLR $11.86
- TBPH $51.40
- Revenue Growth
- MLR N/A
- TBPH 24.49
- 52 Week Low
- MLR $33.81
- TBPH $7.88
- 52 Week High
- MLR $78.25
- TBPH $13.24
- Technical
- Relative Strength Index (RSI)
- MLR 53.47
- TBPH 78.44
- Support Level
- MLR $33.81
- TBPH $11.05
- Resistance Level
- MLR $43.65
- TBPH $11.40
- Average True Range (ATR)
- MLR 1.72
- TBPH 0.43
- MACD
- MLR 0.33
- TBPH 0.20
- Stochastic Oscillator
- MLR 94.31
- TBPH 95.88
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).